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A B S T R A C T   
GM1-gangliosidosis is a lysosomal disease resulting from a deficiency in the hydrolase β-galactosidase (β-gal) and 
subsequent accumulation of gangliosides, primarily in neuronal tissue, leading to progressive neurological 
deterioration and eventually early death. Lysosomal diseases with neurological involvement have limited non- 
invasive therapies due to the inability of lysosomal enzymes to cross the blood-brain barrier (BBB). A novel 
fusion enzyme, labeled mTfR-GLB1, was designed to act as a ferry across the BBB by fusing β-gal to the mouse 
monoclonal antibody against the mouse transferrin receptor and tested in a murine model of GM1-gangliosidosis 
(β-gal− /− ). Twelve hours following a single intravenous dose of mTfR-GLB1 (5.0 mg/kg) into adult β-gal− /− mice 
showed clearance of enzyme activity in the plasma and an increase in β-gal enzyme activity in the liver and 
spleen. Long-term efficacy of mTfR-GLB1 was assessed by treating β-gal− /− mice intravenously twice a week with 
a low (2.5 mg/kg) or high (5.0 mg/kg) dose of mTfR-GLB1 for 17 weeks. Long-term studies showed high dose 
mice gained weight normally compared to vehicle-treated β-gal− /− mice, which are significantly heavier than 
heterozygous controls. Behavioral assessment at six months of age using the pole test showed β-gal− /− mice 
treated with mTfR-GLB1 had improved motor function. Biochemical analysis showed an increase in β-gal enzyme 
activity in the high dose group from negligible levels to 20% and 11% of heterozygous levels in the liver and 
spleen, respectively. Together, these data show that mTfR-GLB1 is a catalytically active β-gal fusion enzyme in 
vivo that is readily taken up into tissues. 
Despite these indications of bioactivity, behavior tests other than the pole test, including the Barnes maze, 
inverted screen, and accelerating rotarod, showed limited or no improvement of treated mice compared to 
β-gal− /− mice receiving vehicle only. Further, administration of mTfR-GLB1 was insufficient to create measur-
able increases in β-gal enzyme activity in the brain or reduce ganglioside content (biochemically and 
morphologically).   
1. Introduction 
Lysosomal diseases are a group of rare, inherited, metabolic disor-
ders that are caused by deficiencies in lysosomal proteins, leading to the 
accumulation of their cellular substrates within the lysosome. Numerous 
therapeutics have been developed and tested for treating lysosomal 
diseases, including enzyme replacement therapy (ERT). However, due to 
their size, lysosomal enzymes are unable to cross the blood-brain barrier 
(BBB), limiting their effect on the neurological pathology. For this 
reason, ERT has not been developed for many lysosomal diseases, 
including GM1-gangliosidosis, which has widespread neurological 
involvement. 
GM1-gangliosidosis results from a deficiency in the lysosomal hy-
drolase β-galactosidase (β-gal; E.C. 3.2.1.23), encoded by the GLB1 gene. 
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β-gal is responsible for the cleavage of terminal β-galactose residues on 
GM1 and GA1 gangliosides, which are a major component of the central 
nervous system (CNS). Patients with the most severe form of the disease, 
the infantile form, exhibit progressive neurodegeneration, including 
profound hypotonia and weakness, global developmental delay, and 
skeletal abnormalities. These patients typically never learn to ambulate 
by crawling or walking. Most patients succumb to the disease by three 
years of age [1,2]. Patients with the late-infantile and juvenile pheno-
types usually learn to walk, but develop ataxia in early childhood and 
eventually become non-ambulatory. Death commonly occurs in early to 
mid-childhood in the late-infantile phenotype and in mid- to late- 
childhood in the juvenile phenotype [3]. Currently, there are no clini-
cally approved treatments for GM1-gangliosidosis. 
ERTs have been developed for many lysosomal diseases (reviewed in 
[4,5]) and high dose ERTs have shown efficacy in achieving neurological 
benefits in animal models [6]; however, none are currently approved for 
treating GM1-gangliosidosis. Preclinical experiments using purified [7] 
and recombinant [8] feline β-gal have been tested in vitro as potential 
therapies for GM1-gangliosidosis, though neither were utilized in animal 
models of the disease to test efficacy. More recently, Condori et al. [9] 
developed and tested a recombinant human β-gal-fusion protein that 
utilized the non-toxic lectin subunit ribosome-inactivating toxin B (RTB) 
of ricin from Ricinus communis as a protein carrier across the BBB. Pre-
viously, fusion of RTB to the deficient protein in the lysosomal disease 
mucopolysaccharidosis type I (MPS I) has shown the ability of delivering 
the enzyme, α-L-iduronidase (IDUA), to the brain in a murine model of 
the disease [10]. In vitro experiments with β-gal:RTB showed that the 
fusion protein was internalized into human fibroblasts, processed into 
the mature form of β-gal, was catalytically active, and reduced gangli-
oside content [9]. Recently, Acosta and Cramer [11] described in their 
review of lectin-mediated delivery of macromolecules into the CNS that 
intravenous administration of β-gal:RTB into β-gal− /− mice resulted in 
measurable β-gal enzyme activity in the CNS and mature β-gal protein in 
the cerebellum and spinal cord of treated mice. However, no data was 
presented. 
An alternative platform for engineering lysosomal enzymes for 
crossing the BBB has been developed, which utilizes genetic fusion of the 
lysosomal enzyme to antibodies [12]. For lysosomal diseases, the lyso-
somal enzyme is fused to a monoclonal antibody against either the 
human insulin receptor (HIR) or the mouse transferrin receptor (mTfR). 
For multiple lysosomal diseases, this approach has been utilized in 
murine experiments, including MPS I (Hurler syndrome) [13], MPS II 
(Hunter syndrome) [14,15] and MPS IIIA (Sanfilippo syndrome type A) 
[16]. Additionally, preliminary safety studies in mice have been pre-
sented for metachromatic leukodystrophy [17]. In MPS I mice, one hour 
following intravenous (IV) administration revealed an increase in α-L- 
iduronidase enzyme activity in the liver, spleen, heart, kidney, serum, 
and brain of treated mice [13]. Following eight weeks of injections, the 
level of glycosaminoglycans (GAG) was reduced in the liver, spleen, and 
heart of treated mice, but not in the kidney or brain, though there was a 
73% reduction in the inclusion bodies in the brain. [13]. Following six 
weeks of intraperitoneal (IP) administration of the fusion protein in MPS 
IIIA mice, the GAG heparan sulfate was significantly reduced in the 
brain and liver of treated mice, whereas the GAG dermatan sulfate was 
only reduced in the liver [16]. Further, motor function assessment uti-
lizing the rotarod showed mice treated with the MPS IIIA fusion protein 
performed better than sham-treated mice. However, treated animals 
were not compared to normal mice. Further, studies in rhesus macaques 
show that these fusion enzymes are capable of penetrating the BBB and 
are safe for repeated IV injections [18,19]. Results from these studies led 
to their use in two clinical trials for MPS I and MPS II (Clinical Trial 
Identifiers MPS I: NCT03071341; MPS II: NCT02262338). For MPS I, the 
results of the phase 1/2 clinical trial showed that 52 weeks of IV treat-
ment with the enzyme valanafusp alpha was well tolerated, with the 
primary adverse reactions being infusion reactions and mild hypogly-
cemia [20]. Further, neurological scores of patients and CSF levels of the 
GAGs heparan and dermatan sulfate were stable during the study. 
However, the study did not compare enrolled patients to a control group 
or natural history data of the MPS I disease, limiting the interpretation of 
the efficacy of this fusion protein. 
In the present study, a novel lysosomal enzyme fusion protein, mTfR- 
GLB1, was tested as a therapy for GM1-gangliosidosis in β-gal deficient 
mice (β-gal− /− ). mTfR-GLB1 is a fusion of the human β-gal enzyme to the 
carboxyl terminus of each heavy chain of a mouse chimeric monoclonal 
antibody against the mouse transferrin receptor (mTfR); therefore, each 
mTfR-GLB1 molecule contains two human β-gal enzymes with a mo-
lecular weight of 292 kDa. This study aimed to test the efficacy of long- 
term intravenous administration of mTfR-GLB1 to determine whether 
this novel fusion enzyme could be utilized as a therapeutic agent for 
treating GM1-gangliosidosis and preventing the onset of the neurolog-
ical symptoms and pathology previously described in the murine model 
of GM1-gangliosidosis [21]. 
2. Materials and methods 
2.1. Expression and purification of mTfR-GLB1 
mTfR-GLB1 was designed and synthesized using established meth-
odologies for monoclonal antibody-lysosomal enzyme fusion proteins 
[12,13,16–19,22–24]. Briefly, a plasmid encoding the sequence of 
mTfR-GLB1 was expressed in stable Chinese hamster ovary cells. The 
supernatant was removed and purified utilizing Protein A purification 
(HiTrap® MabSelect SuRe™, Cytiva Life Sciences, Marlborough, MA). 
The final formulation buffer (or vehicle) was adjusted to 25 mM citrate, 
150 mM NaCl, pH 6.0. 
2.2. Animals and procedures 
All animal care and experimental procedures were conducted under 
the approval of the Institute Animal Care and Use Committee (IACUC) of 
the University of Minnesota. All animals were housed in specific 
pathogen-free conditions. 
GM1-gangliosidosis mice (β-gal− /− ) were generated by targeted 
knockout of 20 bp in exon 8 of the β-gal encoding gene, Glb1 [21]. All 
animals were genotyped by PCR. For short-term assessment, two to six- 
month-old mice received a single intravenous injection of mTfR-GLB1 at 
a dose of 5 mg of mTfR-GLB1 (molecular weight) per kilogram of body 
weight (mg/kg) through the lateral tail vein and euthanized after 12 h. 
For the long-term efficacy study, eight-week-old mice (n = 12 per group; 
n = 6 of each sex) were injected intravenously through the lateral tail 
vein twice per week with a dose of 2.5 or 5.0 mg/kg of mTfR-GLB1 or 
empty vehicle for 17 weeks. Volume was adjusted to 200 μl for each 
injection with vehicle buffer. Following injection of mTfR-GLB1, ani-
mals were monitored for at least one hour for potential adverse events, 
including lethargy, respiratory changes, or other abnormal behavior. If 
mice had an adverse reaction that lasted 30 min or longer, a 10 mg/kg 
dose of diphenhydramine was administered intraperitoneally (IP). Ani-
mals which received diphenhydramine were then given prophylactic 
diphenhydramine for the duration of the study. Mice were monitored 
daily for signs of morbidity and mortality, in addition to weekly weights 
for signs of toxicity to mTfR-GLB1. 
For biochemical analysis, animals were sacrificed by CO2 asphyxia-
tion and perfused via transcardial perfusion with 20 ml of ice-cold 
phosphate-buffered saline. Tissues isolated for biochemical assays 
were flash frozen in liquid nitrogen and stored at − 80 ◦C until assayed. 
2.3. β-Galactosidase (β-gal) enzyme assay 
β-gal enzyme activity was determined utilizing a fluorometric assay 
using 4-methylumbelliferyl-β-D-galactopyranoside (4-MUGal, 
Millipore-Sigma, St. Louis, MO) as the substrate as previously described 
[21]. β-gal enzyme activity was expressed in nmol of 4-MU released per 
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hour, per milligram of protein (nmol/h/mg). Total protein quantifica-
tion was determined using a Pierce™ 660 nm Protein Assay Kit (Thermo 
Fisher Scientific, Waltham, MA). 
2.4. Histopathological analysis 
Following perfusion and fixation with 10% NBF, tissues were pro-
cessed into paraffin wax using standard histology techniques, sectioned 
at a thickness of 4 μm, stained with hematoxylin and eosin (H&E), and 
evaluated using light microscopy by two A.C.V.P. board-certified pa-
thologists (T.C. and M.G.O’S). Additional evaluation was performed on 
selected tissues stained with Luxol fast blue (LFB)/H&E combination 
stain using standard laboratory protocols. All work was done at the 
Masonic Cancer Center Comparative Pathology Shared Resource labo-
ratory at the University of Minnesota. 
2.5. Ganglioside isolation and quantification 
GM1 and GA1 ganglioside levels were quantified as previously 
described [21]. The mouse hippocampus, cerebellum, and cerebral 
cortex tissues were homogenized in 2% CHAPS solution (40 ml/g for 
hippocampus and cerebellum tissues; 10 ml/g for cerebral cortex tissue). 
Protein precipitation with 200 μl of methanol was performed to extract 
GM1 and GA1 from 50 μl of homogenate in the presence of internal 
standards (d3-GM1(18:0) for GM1 and d3-GA1(18:0) for GA1). The 10% 
study sample extracts from each tissue type were pooled to prepare a 
quality control (QC) sample for that tissue. The QC samples were 
injected every 10 study samples to monitor the instrument performance. 
Sample analysis was performed with a Shimadzu 20 CE HPLC system, 
coupled to a 6500QTRAP+ mass spectrometer (AB Sciex, Framingham, 
MA) operated in positive MRM mode. Data processing was conducted 
with Analyst 1.6.3 (Applied Biosystems). The relative quantification of 
lipids is provided, and the data were reported as the peak area ratios of 
the analytes to the corresponding internal standards. 
2.6. Mouse behavior analysis 
Beginning at approximately 24 weeks of age, corresponding to week 
15 of mTfR-GLB1 injections, mice were subjected to a battery of 
behavior tests to assess neuromotor and neurocognitive function. All 
behavioral analyses were conducted in the Mouse Behavior Core at the 
University of Minnesota. 
2.6.1. Neuromotor testing 
2.6.1.1. Inverted screen. Inverted screen testing [25] was completed 
utilizing a wire mesh apparatus, approximately 25 cm × 25 cm with 25 
mm2 square openings, placed approximately 30 cm over a cushioned 
surface. Testing began by placing the mouse on the wire mesh, which 
was then inverted until the animal was completely upside down. Latency 
to fall was measured for a max trial duration of 120 s. Mice were sub-
jected to three trials, with a minimum of a 15-min resting period be-
tween trials. 
2.6.1.2. Pole test. The pole test was conducted as previously described 
with minor modifications [26]. The test began by placing a mouse head- 
upward on a vertical pole (2 cm in diameter; 55 cm tall) wrapped in 
athletic tape to assist with grip. Two measurements were taken: latency 
to rotate body to face downward was measured, and the total time to 
complete the turn and descend the pole and place all four paws on the 
base of the apparatus inside of the cage (i.e. total time to complete the 
test). Maximum test duration was set at 60 s. If a mouse failed to make 
the initial rotation to face downward, 60 s was recorded for both the turn 
and total time to complete the task. If the mouse fell from the pole during 
the testing time, it was placed back at the initial starting point while the 
time continued until 60 s. Mice were subjected to a single trial. 
2.6.1.3. Rotarod. Rotarod analysis was conducted on an accelerating 
rotarod (Ugo Basile, Comerio, Italy), using an adapted protocol 
described previously [27]. Briefly, mice were tested for three consecu-
tive days, undergoing four trials per day, with a minimum inter-trial 
duration of 30 min. Testing was done on a rotarod programmed to 
accelerate from 5 to 50 rpm over a max trial duration of 300 s. Three to 
five mice were placed on the divided rod simultaneously, and the 
apparatus’ counter was started. The trial was considered complete when 
1) the mouse fell off the rotarod and stopped the counter, 2) the mouse 
completes two consecutive rotations by holding on to the rod without 
walking, or 3) when 300 s elapsed. 
2.6.2. Neurocognitive testing 
2.6.2.1. Barnes maze. The Barnes maze [28] was conducted on an 
elevated circular platform, 36 in. in diameter, with 20 equally spaced 
holes around its perimeter. All of the holes on the platform were blocked 
except for one, which contained an opening to an escape box. The 
apparatus was placed directly under a bright light source that served as 
an aversive stimulus for the mouse to escape the platform. Visual cues 
were placed on each of the walls that act as navigational cues for the 
mouse. Mice were trained on the Barnes maze for four days, with each 
mouse subjected to four trials per day, with a max of 3 min per trial, and 
a minimum of 30 min between trials. Data was collected utilizing the 
ANY-Maze software (Stoelting Co, Wood Dale, IL). 
2.7. Statistical analysis 
GraphPad Prism 8 (v. 8.4.2, GraphPad Software, Inc) was used to 
perform all statistical analyses. For enzyme activity, pole test, and 
inverted screen behavior tests, a one-way ANOVA, followed by Dun-
nett’s multiple comparisons test was used. For weight and plasma β-gal 
enzyme activity, a repeated-measures two-way ANOVA, followed by 
Tukey’s multiple comparisons test, was performed. For ganglioside 
quantification, the accelerating rotarod, and Barnes maze, a two-way 
ANOVA, followed by Tukey’s multiple comparisons test was used. Sig-
nificance cutoff of p < 0.05 was used. All values are presented as mean ±
SEM. 
3. Results 
3.1. Catalytic activity of mTfR-GLB1 in vivo 
Preliminary experiments conducted prior to this study comparing 
purified mTfR-GLB1 to recombinant human β-gal enzyme (hβ-gal) 
revealed that mTfR-GLB1 had approximately 17% of hβ-gal enzyme 
activity in vitro, when using molecular weight equivalencies (Tanabe 
Research Laboratories, personal communication). When translated to 
percent of β-gal enzyme activity per mole of β-gal, mTfR-GLB1 has 
approximately 34% of hβ-gal enzyme activity. To test the function of 
mTfR-GLB1 in vivo, a short-term experiment was conducted. Two to six- 
month old β-gal− /− mice were injected with 5.0 mg of mTfR-GLB1 per 
kilogram body weight (mg/kg) of mTfR-GLB1 (n = 4) or vehicle only (n 
= 3) IV through the lateral tail vein. Twelve hours following injection, 
mice were euthanized and β-gal enzyme activity was measured in the 
plasma, brain, heart, liver, spleen, and kidney. β-gal enzyme activity was 
not present in the plasma of treated β-gal− /− mice, suggesting that the 
enzyme was readily taken up into the peripheral tissue within 12 h 
(Fig. 1A). In the liver, β-gal enzyme activity was increased approxi-
mately 12-fold in mTfR-GLB1 treated β-gal− /− mice (46.02 ± 4.95 nmol/ 
h/mg protein) compared to vehicle only β-gal− /− mice (3.86 ± 0.38), 
resulting in approximately 38% of heterozygous (n = 4) β-gal enzyme 
activity (Fig. 1B). While not statistically significant (p = 0.0692), β-gal 
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enzyme activity was increased 8.5-fold in the spleen of mTfR-GLB1 
treated mice (38.67 ± 6.3) compared to β-gal− /− mice receiving 
vehicle only (4.57 ± 0.21) (Fig. 1C). This was approximately 18% of 
heterozygous β-gal enzyme activity. Surprisingly, β-gal enzyme activity 
was not increased above β-gal− /− mice receiving vehicle only in the 
brain, heart, or kidney (Fig. 1D, E, F). Overall, these results showed that 
mTfR-GLB1 was readily taken up into the tissue and was catalytically 
active in a murine model of GM1-gangliosidosis. 
Two to six-month-old β-gal− /− mice were injected intravenously 
with 5.0 mg/kg of mTfR-GLB1 (n = 4) or empty vehicle (n = 3). Control 
heterozygous β-gal+/− mice (n = 4) were also treated IV with empty 
vehicle. 12-h following treatment, animals were euthanized and β-gal 
enzyme activity was measured in the (A) plasma, (B) liver, (C) spleen, 
(D) brain, (E) heart, and (F) kidney. Mean ± SEM. ***p < 0.001 when 
comparing mTfR-GLB1 treated β-gal− /− mice to vehicle only β-gal− /−
mice. One-way ANOVA with adjustments for multiple comparisons. 
3.2. Long-term efficacy of mTfR-GLB1 in preventing disease onset in a 
murine model of GM1-gangliosidosis 
To test whether mTfR-GLB1 could prevent the onset of disease, mice 
were treated for 17 weeks with twice weekly IV injections of mTfR- 
GLB1, beginning at eight weeks of age. For this experiment, mice were 
randomly assigned into one of six experimental groups (Table 1). Two 
groups served as baseline controls for ganglioside quantification, which 
included six heterozygous mice (β-gal+/− ) and six β-gal− /− mice, with 
equal numbers of females and males. These mice were euthanized and 
analyzed at eight weeks of age. The four remaining groups included two 
control groups, β-gal+/− and β-gal− /− mice receiving vehicle only, one 
group of β-gal− /− receiving a low dose of mTfR-GLB1 (2.5 mg/kg) and 
another group of β-gal− /− mice receiving a high dose of mTfR-GLB1 (5.0 
mg/kg). Each group consisted of eight female and eight male mice, 
resulting in a total of 16 animals in each group. Injections were 
continued for a total of 17 weeks, or 34 injections. For the duration of 
the study, weights were recorded weekly and animals were monitored 
for onset of disease. Additionally, plasma was collected every four weeks 
to measure β-gal enzyme activity. Beginning at 24 weeks of age, mice 
were subjected to a battery of behavioral tests to quantify neuromotor 
and neurocognitive function. Twenty-four hours following the final in-
jection, mice were euthanized, and tissues were collected. Study animals 
were randomly selected to have the left hemisphere of the brain utilized 
either for histopathological analysis or for measuring β-gal enzyme ac-
tivity. Further, β-gal enzyme activity was measured in the liver, spleen, 
kidney, and heart of all mice. For all animals, the right hemisphere of the 
brain was microdissected to remove the hippocampus, cerebellum, and 
cerebral cortex, which were utilized to measure ganglioside levels. 
Overall, IV administration with mTfR-GLB1 was tolerated over the 
duration of the study. At the end of the study, all female β-gal− /− mice 
receiving mTfR-GLB1, except one mouse receiving the low dose, were 
receiving prophylactic diphenhydramine. In contrast, only two male 
β-gal− /− mice receiving the low dose and three receiving the high dose 
were receiving prophylactic diphenhydramine. In most instances, 
adverse reactions observed after administration of mTfR-GLB1 included 
lethargy and respiratory changes. While all male mice in the experiment 
survived, two female β-gal− /− mice were lost during the study. One 
β-gal− /− female receiving vehicle only became emaciated nine weeks 
into the study and required euthanasia. Post-mortem observations 
revealed severe splenomegaly. The second mouse that was lost during 
Fig. 1. β-galactosidase enzyme activity 12-h post-injection with mTfR-GLB1.  
Table 1 
Experimental design.  
Group Group designation No. of animals Total mTfR-GLB1 dose 
(mg/kg) 
Male Female 
1 β-gal− /− , Baseline 3 3 0 
2 Heterozygotes, Baseline 3 3 0 
3 β-gal− /− , Vehicle only 8 8 0 
4 Heterozygotes, Vehicle 
only 
8 8 0 
5 β-gal− /− , Low dose 8 8 2.5 
6 β-gal− /− , High dose 8 8 5.0  
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the study was a β-gal− /− mouse that was receiving a high dose of mTfR- 
GLB1. This mouse became severely lethargic following mTfR-GLB1 
administration and did not recover and a decision was made to eutha-
nize the animal. 
3.3. Male β-gal− /− mice receiving high dose of mTfR-GLB1 are 
significantly lighter than vehicle only β-gal− /− mice 
For the duration of the experiment, mice were weighed weekly prior 
to the administration of the first dose of mTfR-GLB1. Previous charac-
terization studies have shown that male β-gal− /− mice become signifi-
cantly heavier than heterozygous and wildtype littermates [21]. In this 
study, similar findings were observed, where the weights of female 
β-gal− /− mice (Fig. 2A) were not significantly different than heterozy-
gotes. Interestingly, throughout the study, the weights of male β-gal− /−
mice receiving the high dose of mTfR-GLB1 were lower than vehicle only 
β-gal− /− mice, even significantly at various points throughout the study 
(Fig. 2B). Further, the weights of male β-gal− /− mice that received the 
low dose of mTfR-GLB1 trended lower than β-gal− /− mice receiving 
vehicle only. Overall, there was an observable dose-weight response for 
male β-gal− /− mice receiving mTfR-GLB1. 
3.4. Presence of β-galactosidase enzyme activity in the liver and spleen of 
β-gal− /− mice treated with mTfR-GLB1 
Plasma was first collected 24 h prior to the first administration of 
mTfR-GLB1 and β-gal enzyme activity was measured. Plasma was then 
collected every four weeks, 24 h after the second weekly injection. Both 
groups receiving mTfR-GLB1 had no measurable increase in β-gal 
enzyme activity over β-gal− /− mice receiving vehicle only at the time 
points assessed (Fig. 3A). This further suggests that mTfR-GLB1 is 
readily taken up into the peripheral tissues following IV administration. 
At the conclusion of the study, β-gal enzyme activity was also 
measured in multiple tissues, 24 h following the final administration of 
mTfR-GLB1. In the liver, β-gal− /− mice receiving the low dose of mTfR- 
GLB1 had 4.7-fold higher β-gal enzyme activity (9.76 ± 1.45 nmol/h/mg 
protein) and mice that received the high dose of mTfR-GLB1 were 7.5- 
fold higher (15.51 ± 2.69) compared to vehicle-treated β-gal− /− mice 
(2.06 ± 0.13) (Fig. 3B). In the spleen, enzyme activity was also increased 
2.4-fold (14.2 ± 1.66) in mice receiving the low dose and 5.0-fold 
(29.63 ± 5.98) in mice receiving the high dose of mTfR-GLB1 
compared to vehicle only β-gal− /− mice activity (5.93 ± 0.45) 
(Fig. 3C). However, in both mTfR-GLB1 treatment groups, β-gal enzyme 
activity in the brain, heart, and kidney did not increase above vehicle 
only β-gal− /− levels (Figs. 3D, E, F). 
3.5. No reduction of ganglioside content in the brain of mTfR-GLB1 
treated mice 
To determine if long-term treatment of GM1-gangliosidosis mice 
with mTfR-GLB1 reduced or prevented the accumulation of storage 
material in the brain, GM1 and GA1 ganglioside levels were measured in 
the cerebral cortex, cerebellum, and hippocampus (Fig. 4A, B, C). At 
eight weeks of age, ganglioside levels in baseline β-gal− /− mice were 
already significantly elevated compared to heterozygous β-gal+/− con-
trols in all tissues assayed. Additionally, as the disease progressed be-
tween two months of age when the study was initiated and the end of the 
study at six months of age, ganglioside content increased 5–54% in the 
cerebral cortex, 8–45% in the cerebellum, and 26–50% in the 
hippocampus. 
After 17 weeks of treatment, β-gal− /− mice treated with either the 
low dose or high dose of mTfR-GLB1 showed no reduction in the 
ganglioside content in the cerebral cortex, cerebellum, or hippocampus. 
This further supports that mTfR-GLB1 does not cross the BBB as designed 
or that the relatively low enzyme activity of the fusion protein is not 
sufficient to reduce the substrate in the brain. 
3.6. Partial improvement of motor function in mice treated with mTfR- 
GLB1 
At approximately 24 weeks of age, mice were subjected to a battery 
of behavioral tests to assess whether treatment with mTfR-GLB1 could 
improve neuromotor and neurocognitive function. To assess motor 
function, specifically bradykinesia, the pole test was used. Both the low 
and high dose groups had a significant improvement (p < 0.05 and p <
0.001, respectively) in their ability to coordinate their limbs and invert 
their body on the pole, whereas the β-gal− /− mice receiving vehicle only 
had extreme difficultly completing this task (Fig. 5A). Moreover, mice 
receiving the high dose of mTfR-GLB1 had a significant reduction (p <
0.01) in the time it took to complete the entire task of turning and 
descending the pole compared to vehicle-treated β-gal− /− mice 
(Fig. 5B). Overall, there was an observed dose-response in the ability of 
the mice to complete the pole test. 
Additional testing was conducted to elucidate whether motor or 
Fig. 2. Effects of mTfR-GLB1 on weight of β-gal− /− mice. For the duration of the study, the weights of (A) female mice and (B) male mice were measured and 
recorded weekly. Mean ± SEM. All groups n = 8, except (A) Female β-gal− /− control and high dose (n = 7). *p < 0.05 when comparing high dose treated to vehicle- 
treated β-gal− /− mice; **p < 0.01. Repeated-measures two-way ANOVA, followed by Tukey’s multiple comparisons test. 
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neurocognitive function was preserved in β-gal− /− mice treated with 
mTfR-GLB1. To assess grip strength, the inverted screen was used. In this 
test, β-gal− /− mice treated with mTfR-GLB1 showed no improvement in 
their ability to remain on the inverted screen, performing similarly to 
vehicle-treated β-gal− /− mice, suggesting that grip strength was not 
maintained (Fig. 6A). Motor function and coordination were further 
assessed using the accelerating rotarod. Similar to the inverted screen, 
β-gal− /− mice treated with mTfR-GLB1 performed comparably to 
vehicle-treated β-gal− /− mice (Fig. 6B). 
To assess cognitive function, the Barnes maze was utilized. While 
heterozygous β-gal+/− mice learned the task and escaped the platform in 
under 60 s on the final testing day, vehicle-treated β-gal− /− mice failed 
to learn the task. Similar to β-gal− /− mice receiving vehicle only, mice 
treated with the low and high dose of mTfR-GLB1 failed to learn and 
complete the task, exhibiting neurocognitive impairment (Fig. 6C). 
3.7. Brain histopathological analysis revealed presence of severe neuronal 
pathology in mice treated with mTfR-GLB1 
When the mice were six months of age, the histology from the left 
hemisphere of the brains was analyzed to determine whether mTfR- 
GLB1 reduced or prevented the neuronal vacuolation described 
Fig. 3. Plasma and tissue β-gal enzyme activity. (A) Plasma enzyme activity was measured prior to study initiation and 24-h following IV administration of mTfR- 
GLB1 every four weeks for the duration of the study. For (B) to (F), mice were euthanized 24-h following the final treatment of mTfR-GLB1 (week 17), perfused with 
phosphate buffered saline and tissues were collected and analyzed for β-gal enzyme activity as described in the materials and methods. Mean ± SEM. *p < 0.05 when 
comparing treated to vehicle only β-gal− /− mice; **p < 0.01; ****p < 0.0001. (A) Repeated-measures two-way ANOVA, followed by Tukey’s multiple comparisons 
test; (B)-(F) One-way ANOVA, followed by Dunnett’s multiple comparisons test. 
Fig. 4. GM1 and GA1 ganglioside quantification in the brain of mice treated with mTfR-GLB1. Ganglioside levels were measured using high performance liquid 
chromatography tandem-mass spectrometry in the (A) cerebral cortex, (B) cerebellum, and (C) hippocampus. Mean ± SEM. Two-way ANOVA, followed by Tukey’s 
multiple comparisons test. 
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previously. The brain tissue of vehicle-treated β-gal− /− mice had 
neuronal lesions, consistent with the GM1-gangliosidosis phenotype 
(Fig. 7B). This was characterized by swollen neurons that contained 
clear to pale-eosinophilic, well-demarcated intracytoplasmic vacuoles, 
occasional fine-granulation, displacement of the Nissl substance, and 
occasional nuclear margination. These lesions are moderate to marked 
and present in all areas of the brain, including the cerebellum, pons, 
thalamus, hypothalamus, and cerebral cortex. In contrast, all of these 
observations were absent from the heterozygous β-gal+/− brain tissue. 
Further, the intracellular storage material in the affected neurons 
stained positively with Luxol fast blue (Fig. 8B). Analysis of the brain 
samples from β-gal− /− mice that received low (Fig. 7C) and high 
(Fig. 7D) doses of mTfR-GLB1 for 17 weeks revealed the presence of 
neuronal vacuolation that was comparable to that observed in β-gal− /−
mice receiving vehicle only. Further, similar to vehicle-treated β-gal− /−
mice, this intracellular storage material stained positively with Luxol 
fast blue (Fig. 8C and D). 
4. Discussion 
The treatment of lysosomal diseases with ERT using recombinant 
native enzymes has been beneficial for thousands of patients suffering 
from these diseases. However, these enzymes continue to lack neuro-
logical benefit due to the inability of the lysosomal enzyme to cross the 
BBB. To solve this problem, fusion enzymes have been developed, which 
allows for the enzyme to bind to a receptor that is present on the 
epithelial cells of the BBB and undergo receptor-mediated transcytosis. 
The present study describes the assessment of such a protein, mTfR- 
GLB1, as a potential therapy for GM1-gangliosidosis. mTfR-GLB1 fuses 
the human β-gal enzyme to the carboxyl terminus of each heavy chain of 
a mouse chimeric monoclonal antibody against the mouse transferrin 
receptor, meaning there are two human β-gal enzymes present in each 
molecule. The data presented shows that mTfR-GLB1 is cleared from the 
bloodstream within 12 h following intravenous administration, as 
demonstrated by the lack of β-gal enzyme activity in the plasma of 
treated mice. mTfR-GLB1 has also been shown to be catalytically active 
and capable of catabolizing the synthetic substrate 4-methylumbelliferyl 
β-D-galactopyranoside used in β-gal enzyme assays, as shown by liver 
and spleen enzyme activity. Additionally, weight measurements over 
the duration of the study showed the weight of male β-gal− /− mice 
receiving the high dose of mTfR-GLB1 was significantly lower than 
β-gal− /− mice receiving vehicle only, displaying weights closer to that of 
the heterozygous control group. Further, behavioral assessment at six 
months of age using the pole test revealed improved motor function in 
mice receiving the high dose of mTfR-GLB1. 
At eight weeks of age, ganglioside content in β-gal− /− mice was 
already elevated compared to normal heterozygous β-gal− /− mice. 
Further, by the end of the study at six months of age, there was a pro-
gressive accumulation of gangliosides as the disease advanced, dis-
played by a significant increase in ganglioside content in six-month-old 
Fig. 5. Assessment of fine motor coordination using the pole test in mice receiving mTfR-GLB1. At six months of age, fine motor skills were tested using the pole test, 
where animals were placed on a vertical pole facing upwards and the (A) time to invert and face downward was measured. Additionally, the (B) total time to 
complete the inversion and descend the pole was measured. Mean ± SEM. *p < 0.05 when comparing treated to vehicle-treated β-gal− /− mice; **p < 0.01; ***p <
0.001. One-way ANOVA, followed by Dunnett’s multiple comparisons test. 
Fig. 6. Further behavioral evaluation of motor and neurocognitive function of β-gal− /− mice treated with mTfR-GLB1. At six months of age, mice were subjected to 
additional behavioral analyses. (A) Grip strength was assessed by placing mice on an inverted wire screen and timing the latency to fall. (B) Motor coordination was 
tested using the accelerating rotarod, where the latency to fall is measured. (C) To assess neurocognitive function, mice were subjected to the Barnes maze, which 
requires mice to learn to locate and escape the brightly-lit platform over the four day duration of the test. Mean ± SEM. (A) One-way ANOVA, followed by Dunnett’s 
multiple comparisons test; (B and C) Repeated-measures two-way ANOVA, followed by Tukey’s multiple comparisons test. 
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β-gal− /− mice receiving vehicle only. While this is the first observation 
of ganglioside accumulation early in adulthood in the β-gal− /− model 
used in this study, a similar result has been described in another murine 
model of GM1-gangliosidosis [29–31]. Though treatment with mTfR- 
GLB1 improved pole test results and mouse weight, full cognitive and 
motor function was not improved. A possible interpretation of the 
improved motor function in the pole test is that mTfR-GLB1 provided 
enough β-gal enzyme activity to increase the physical activity of β-gal− / 
− mice. This increase in activity then could have contributed to the 
observed weight reduction, which resulted in less of a burden on the 
animals during a physical test such as inverting and descending a ver-
tical pole. With significant ganglioside accumulation already present at 
eight weeks of age, it is possible that even with therapeutic intervention 
using mTfR-GLB1 or another approach, irreparable neurological damage 
has been done and earlier treatment is necessary. 
In contrast to biodistribution studies testing similar mTfR-lysosomal 
enzyme fusion proteins, β-gal enzyme activity was not detected in the 
heart, kidney, or brain of treated β-gal− /− mice at 12- and 24-h following 
treatment. Prior studies with mTfR fused to IDUA have shown that IDUA 
enzyme activity was increased in the heart, kidney, brain, liver, spleen, 
and serum one hour following IV administration in IDUA-deficient mice 
[13]. Further, brain ganglioside levels were not reduced in mTfR-GLB1 
treated β-gal− /− mice compared to vehicle-treated β-gal− /− mice. In 
another study, Boado et al. [16] showed that one week following the 
final dose of a six-week treatment with the mTfR-lysosomal enzyme 
fusion protein that heparan sulfate levels were significantly reduced in 
the brain of MPS IIIB mice compared to sham-treated MPS IIIB mice. 
Together, this data suggests mTfR-GLB1 has reduced biodistribution or a 
Fig. 7. Neurological pathology in β-gal− /− mice treated with mTfR-GLB1. Hematoxylin and eosin staining of cerebellar tissue from the brain of six-month-old (A) 
normal β-gal+/− mice, (B) vehicle-treated β-gal− /− mice, (C) β-gal− /− mice treated with 2.5 mg/kg of mTfR-GLB1 and (D) β-gal− /− mice treated with 5.0 mg/kg of 
mTfR-GLB1. Arrows indicate examples of Purkinje neurons with intracytoplasmic vacuoles. Objective x60, scale bar indicates 50 μm. 
Fig. 8. Luxol fast blue staining of intracellular stor-
age material in mice treated with mTfR-GLB1. Luxol 
fast blue staining of neurons in the cerebellum of six- 
month-old (A) heterozygous β-gal+/− mice, (B) 
vehicle-treated β-gal− /− mice, (C) β-gal− /− mice 
treated with 2.5 mg/kg of mTfR-GLB1 and (D) 
β-gal− /− mice treated with 5.0 mg/kg of mTfR-GLB1. 
Arrows illustrate Purkinje neurons with intra-
cytoplasmic vacuoles that contain intracellular stor-
age material stained positive with Luxol fast blue. 
Objective x60, scale bar indicates 50 μm.   
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short half-life compared to these other mTfR-fusion enzymes. 
Additionally, the absence of a therapeutic benefit in treating the 
GM1-gangliosidosis pathology in β-gal− /− mice with mTfR-GLB1 can 
potentially also be attributed to the instability of the human β-gal 
enzyme. Human β-gal is known to form a dynamic multi-enzyme com-
plex with neuraminidase 1 (NEU1) and protective protein cathepsin A 
(PPCA) [32], which plays a role in intracellular stability of human β-gal. 
Recently, Chen et al. [31] demonstrated that recombinant human β-gal 
formed stable homodimers under acidic conditions at a concentration of 
0.1 mg/ml, whereas at a neutral pH, the enzyme became unstable and 
was predominantly found as a monomer. Further, while human β-gal 
enzyme can be either in a multi-enzyme complex or as a homodimer, the 
half-life is extended from a few hours to several days when in complex 
with NEU1 and PPCA [33]. In cell culture experiments, β-gal-deficient 
human fibroblasts transduced with retroviruses expressing human β-gal 
[34] or transfected with plasmids expressing human β-gal [35] revealed 
no or minimal β-gal enzyme activity in the cell culture media. Further, 
Lambourne and Potter [35] showed that the catalytic activity of human 
β-gal was dependent on temperature, showing reduced enzymatic ac-
tivity at 37 ◦C, which is the standard human biological temperature. In 
contrast, the mouse β-gal enzyme provided higher enzyme activity in 
β-gal-deficient human fibroblasts in cell lysates and the culture media 
and was very thermostable [34,35]. 
In addition to the stability of the human β-gal enzyme, the lack of 
therapeutic efficacy of mTfR-GLB1 could be due to the structure of the 
mTfR-GLB1 protein. Studies have shown that the presence or location of 
the receptor-binding component of the engineered enzyme can signifi-
cantly impact enzyme activity, for example, in β-glucuronidase [23], 
which is the deficient enzyme in the lysosomal disease MPS VII (Sly 
syndrome), and β-galactosidase in GM1-gangliosidosis [9]. In vitro 
studies showed that the synthetic mTfR-GLB1 enzyme, which is 
comprised of two human β-gal enzymes, had 17% of the β-gal enzyme 
activity as the recombinant human β-gal enzyme (unpublished data, 
Tanabe Research Laboratories USA, Inc.). In the present murine study, 
mice receiving the low and high dose of mTfR-GLB1 had approximately 
12.5% and 20% of heterozygous levels of β-gal activity in the liver, 
respectively. It was previously reported that approximately 1% of the 
injected dose of the lysosomal enzyme fusion protein designed for MPS I 
crosses the BBB [18]. However, with such a relatively low enzyme ac-
tivity present in the peripheral tissue, measuring 1% of the injected dose 
may be outside of the limits of detection of the β-gal enzyme assay. Even 
so, if β-gal enzyme activity were measured in the brain, the present study 
showed that long-term IV administration of mTfR-GLB1 at the current 
doses provided limited benefits for preventing the onset of the GM1- 
gangliosidosis phenotype and did not reduce ganglioside accumulation 
in the brain. Recently, Boado et al. [24] re-designed and tested the 
catalytic activity of a new human β-gal fusion enzyme. This enzyme, 
termed HIRMAb-HC-LL-GLB1, includes a different linker (LL) sequence 
between the β-gal enzyme and the monoclonal antibody against the 
human insulin receptor (HIRMAb), compared to the mTfR-GLB1. This 
modification resulted in the restoration of β-gal enzyme activity up to 
93% of recombinant human β-gal enzyme activity [24]. Whether or not 
this modification to increase β-gal enzyme activity results in a thera-
peutic benefit for GM1-gangliosidosis has yet to be elucidated. 
Overall, improved motor function in the pole test indicates a 
response to therapy with mTfR-GLB1, but not sufficient to result in a 
demonstrative improvement in the Barnes maze, accelerating rotarod, 
and inverted screen. The association of animal weight with dose of 
mTfR-GLB1, which may have contributed to improved motor abilities on 
the pole test, suggests a possible dose-response effect. Administration of 
mTfR-GLB1 was initiated after affected mice reached adulthood and 
importantly, a profound pathologic accumulation of ganglioside was 
shown to be present in the CNS of affected β-gal− /− mice prior to the age 
of initiation of mTfR-GLB1 administration. Would dosing earlier in 
disease course, when less neurological damage has occurred, allow for a 
better therapeutic response? King et al. [3] has described a timeline of 
clinical changes that occur in the infantile and juvenile gangliosidoses 
through a clinical perspective natural history study. The gangliosidoses 
are chronically progressive, but a critical window of time exists in which 
the patients do not show overt signs of their gangliosidosis condition. 
Children with the most severe infantile phenotype often appear healthy 
at birth and have normal Agpar scores. Signs of neurological impairment 
do not become apparent until four to six months of age, at which time 
fine and gross motor skills markedly decline, leading parents and care-
givers to seek a diagnosis. Cognitive abilities also begin to show decline 
at this time or shortly thereafter [2]. Children with the classic juvenile 
phenotype meet their first-year milestones. Signs of disease leading 
caregivers to seek a diagnosis typically do not occur until after the third 
to fifth year of life, and most often initially present as changes in 
ambulation skills and language skills. In an intermediate form, the late- 
infantile phenotype, patients meet first-year development milestones, 
followed by appearance of marked changes in ambulation and language 
skills [3]. Considering the severe and progressive neurological impair-
ment that occurs in the gangliosidoses and concerns about irreversibility 
of neurological damage, an effective therapy may require therapy 
initiation to occur early, before disease symptoms are apparent. The 
encouraging results of the pole test and observed weight normalization 
in the high dose of mTfR-GLB1 suggest that such variations as a higher 
dose, genetic modification of the fusion protein to accomplish higher 
enzyme activity or earlier treatment with mTfR-GLB1 might elicit a 
clearer therapeutic cognitive and motor skill improvement. 
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